Insights
Insights From Our Experts
Articles
A Review of Worldwide Indirect Treatment Comparison (ITC) Guidelines and Best Practices
Posted by
Krista Tantakoun , Christopher Olsen , Fatemeh Mirzayeh Fashami , Imtiaz Samjoo , Chris Cameron, PhD on June 12, 20246/12/24
Considering the challenges of conducting head-to-head clinical trials, indirect treatment comparisons (ITCs) offer valuable insights into clinical effectiveness that reflect current and local practices. These insights can help regulators and reimbursement agencies make better-informed decisions, thereby…
Championing Women’s Health and Equity
At Radical Health Festival Helsinki, Sr Innovation Manager, Anastasiya Markvarde, moderated a women-led panel on Closing the Funding Gaps. In this piece, we’re sharing Anastasiya’s takeaways from the session, steering the conversation toward twocritical gaps: the…
FDA Guidance and Considerations for Scientific Exchange Communication Strategies
In light of draft guidance issued by the U.S. Food and Drug Administration (FDA) regarding the communication of scientific information of unapproved uses (SIUU) of approved medical medical products, EVERSANA continues to assess the potential risk…
Updated Guidance May Ease MDR Transition for SaMD Manufacturers
The regulation of medical devices in the EU has been chaotic since the implementation of Regulation (EU) 2017/745, known as the Medical Device Regulation (MDR). This upheaval has been particularly challenging for manufacturers facing a backlog…
Navigating the Evolution of Precision Medicine: Data-Driven Strategies for Life Sciences Commercialization
The landscape of pharmaceutical commercialization has undergone a remarkable transformation over the past decade. Traditional blockbuster drugs, once the hallmark of the industry, have given way to other products such as targeted therapeutics designed for rare…
M&A and BD&L Outlook and Perspectives on Commercial Due Diligence
In this webinar, industry leaders Faruk Abdullah, Jakub Pijewski, PhD, and Yao Zhang, PhD, delve into the dynamic world of M&A, BD&L, and Commercial Due Diligence (CDD) in the pharmaceutical and biotech sectors. Gain valuable insights into:…
Optimizing Patient-Centered Care: Strategies for Improving Health Outcomes
With a rapidly evolving health insurance landscape in India, it is imperative to understand the challenges and potential solutions for innovative medical technologies reimbursement by private health insurance in India. EVERSANA recently partnered with St. Jude…
Bridging “Share of Voice” with “Share of Influence” for Lasting Impact
In today’s complex healthcare environment, manufacturers must navigate an evolving stakeholder landscape to guarantee patient access and successful product launches. This article explores how deploying a strategic approach that establishes a “share of influence” across the…
Celebrating Excellence: Two EVERSANA Leaders Named to PM360 Elite 100 List
We’re excited to share that two EVERSANA leaders have been recognized in the prestigious 2024 PM360 ELITE 100 List. PM360 ELITE celebrates individuals who exemplify excellence and innovation in the healthcare industry. Highlighted among this year’s…
Integrated Delivery Networks (IDNs): Driving Change in Drug Access and Utilization
As of May 2024, a striking 77.6% of physicians in the United States are employed by hospitals, health systems and corporate entities – a significant surge from less than 50% a mere decade ago. This trend…